Factors correlating with acoustic radiation force impulse elastography in chronic hepatitis C

Nishikawa, Toru; Hashimoto, Senju; Kawabe, Naoto; Harata, Masao; Nitta, Yoshifumi; Murao, Michihito; Nakano, Takuji; Mizuno, Yuko; Shimazaki, Hiroaki; Kan, Toshiki; Nakaoka, Kazunori; Takagawa, Yuka; Ohki, Masashi; Ichino, Naohiro; Osakabe, Keisuke; Yoshioka, Kentaro

doi:10.3748/wjg.v20.i5.1289

Cited by 33 publications

(28 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The same limitation has been observed in some studies with PSWSM(Takahashi et al 2010;Yoon et al 2012;Chen et al 2012), but not in others(Friedrich-Rust et al 2009a;Palmeri et al 2011;Rizzo et al 2011;Nishikawa et al 2014).…”

mentioning

confidence: 59%

WFUMB Guidelines and Recommendations for Clinical Use of Ultrasound Elastography: Part 3: Liver

Barr

Nakashima

Amy

et al. 2015

Ultrasound in Medicine & Biology

683

577

View full text Add to dashboard Cite

The World Federation for Ultrasound in Medicine and Biology (WFUMB) has produced these guidelines for the use of elastography techniques in liver disease. For each available technique, the reproducibility, results, and limitations are analyzed, and recommendations are given. Finally, recommendations based on the international literature and the findings of the WFUMB expert group are established as answers to common questions. The document has a clinical perspective and is aimed at assessing the usefulness of elastography in the management of liver diseases.

show abstract

mentioning

confidence: 59%

WFUMB Guidelines and Recommendations for Clinical Use of Ultrasound Elastography: Part 3: Liver

Barr

Nakashima

Amy

et al. 2015

Ultrasound in Medicine & Biology

683

577

View full text Add to dashboard Cite

show abstract

“…High inflammatory activity causes high LSM values in chronic viral hepatitis . High body mass index (BMI) causes lower ARFI values in chronic hepatitis C (CHC) with no or mild fibrosis …”

Section: Introductionmentioning

confidence: 99%

Measurement of liver stiffness as a non‐invasive method for diagnosis of non‐alcoholic fatty liver disease

Yoshioka

Hashimoto

Kawabe

2014

Hepatology Research

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is one of the major causes of liver disease worldwide. To detect early stages of NAFLD and start treatment or to monitor the changes in trials of new drugs, non-invasive diagnostic methods are needed, such as biochemical markers or liver stiffness measurement (LSM). LSM with transient elastography (TE) and acoustic radiation force impulse (ARFI) has been shown to be useful in NAFLD, although the cut-off values have varied among reports. Magnetic resonance elastography and real-time tissue elastography also can be useful for the diagnosis of NAFLD, although the number of studies is limited. Fibrosis is absent in 8-40% of patients with nonalcoholic steatohepatitis (NASH), making it difficult to diagnose NASH by LSM because LSM is usually associated with fibrotic stage. The presence of inflammation or hepatocyte ballooning may affect LSM and aid the diagnosis of NASH without fibrosis. However, obesity significantly increases the failure of LSM and its interference is more conspicuous in TE than in ARFI. The newly implemented XL probe of TE has overcome the difficulty to some degree. Nonetheless, the effects of obesity, hepatocyte ballooning, steatosis and inflammation on LSM values have not yet been adequately investigated, although they are likely to affect LSM values. Further studies are needed to establish the clinical utility of LSM in NAFLD.

show abstract

“…The details of ARFI measurement procedure have been described in a previous report. [16] Albumin levels To assess the factors associated with albumin elevation, the patients were divided into three groups according to their baseline albumin levels: group A, ≥ 4 g/dL; group B, 3.6-3.9 g/dL; and group C, ≤ 3.5 g/dL.…”

Section: Acoustic Radiation Force Impulse (Arfi) Measurementmentioning

confidence: 99%

Increase in albumin by daclatasvir/asunaprevir therapy is correlated with decrease in aspartate transaminase

Kan

Hashimoto

Kawabe

et al. 2017

Journal of Translational Internal Medicine

View full text Add to dashboard Cite

Objective: To elucidate the mechanism of an increase in the albumin levels by daclatasvir (DCV)/asunaprevir (ASV) therapy, we assessed the factors associated with an increase in the albumin levels. Methods: We retrospectively analyzed 125 patients with chronic hepatitis C virus (HCV) infection, treated with DCV/ASV from November 2014 to January 2016. Results: Albumin levels significantly increased from 4.0 ± 0.4 g/dL at baseline to 4.2 ± 0.4 g/dL at 24 weeks after the end of treatment (EOT) (P < 0.0001) in 108 patients with SVR. Patients with SVR were divided into three groups according to their baseline albumin levels: group A, ≥ 4 g/dL; group B, 3.6-3.9 g/dL; and group C, ≤ 3.5 g/dL. The increase in albumin levels from baseline to at 24 weeks after EOT was significantly larger in group C (0.5 ± 0.5 g/dL, P < 0.0001) and group B (0.2 ± 0.4 g/dL, P = 0.0059) than in group A (0.0 ± 0.3 g/dL). Multivariate analysis showed that aspartate transaminase (AST) levels was the only factor associated with ≥ 0.3 g/dL increase in albumin levels in groups B and C (P = 0.0305). An increase in albumin levels was significantly correlated with a decrease in AST levels (r = 0.4729, P = 0.0119). Conclusion: DCV/ASV therapy resulted in an increase in albumin levels in SVR patients, which was significantly correlated with a decrease in AST levels. It is probable that the reduction of inflammation, but not by reduction of fibrosis, mainly caused an increase in albumin levels.

show abstract

Factors correlating with acoustic radiation force impulse elastography in chronic hepatitis C

Abstract: ARFI correlated with fibrosis stage and hyaluronic acid but not with inflammation. ARFI was affected by BMI, γ-glutamyltranspeptidase, and hyaluronic acid in each fibrosis stage.

Cited by 33 publications

References 32 publications

WFUMB Guidelines and Recommendations for Clinical Use of Ultrasound Elastography: Part 3: Liver

WFUMB Guidelines and Recommendations for Clinical Use of Ultrasound Elastography: Part 3: Liver

Measurement of liver stiffness as a non‐invasive method for diagnosis of non‐alcoholic fatty liver disease

Increase in albumin by daclatasvir/asunaprevir therapy is correlated with decrease in aspartate transaminase

Contact Info

Product

Resources

About